CALA Stock - Calithera Biosciences, Inc.
Unlock GoAI Insights for CALA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | $9.75M | N/A | N/A | $22.25M |
| Gross Profit | $-1,385,000 | $8.32M | $-1,870,000 | $-1,845,000 | $22.25M |
| Gross Margin | N/A | 85.3% | N/A | N/A | 100.0% |
| Operating Income | $-42,074,000 | $-114,277,000 | $-91,387,000 | $-92,895,000 | $-57,281,000 |
| Net Income | $-18,866,000 | $-115,088,000 | $-88,523,000 | $-86,346,000 | $-51,472,000 |
| Net Margin | N/A | -1180.4% | N/A | N/A | -231.3% |
| EPS | $-7.94 | $-31.16 | $-26.20 | $-36.50 | $-28.12 |
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Visit WebsiteEarnings History & Surprises
CALAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Mar 29, 2024 | — | — | — | — |
Q4 2023 | Nov 13, 2023 | — | — | — | — |
Q3 2023 | Aug 23, 2023 | — | — | — | — |
Q1 2023 | Mar 30, 2023 | $-1.49 | $-1.42 | +4.7% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $2.83 | — | — |
Q4 2022 | Nov 14, 2022 | $-1.99 | $-2.01 | -1.0% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-2.70 | $-1.59 | +41.1% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-3.40 | $-3.60 | -5.9% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-31.99 | — | — |
Q4 2021 | Nov 9, 2021 | $-4.60 | $-3.00 | +34.8% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-4.60 | $-3.80 | +17.4% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-5.40 | $-5.60 | -3.7% | ✗ MISS |
Q1 2021 | Mar 16, 2021 | $-6.40 | $-6.40 | 0.0% | = MET |
Q4 2020 | Nov 5, 2020 | $-6.20 | $-6.40 | -3.2% | ✗ MISS |
Q3 2020 | Aug 10, 2020 | $-6.60 | $-5.80 | +12.1% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $-7.40 | $-7.60 | -2.7% | ✗ MISS |
Q1 2020 | Mar 11, 2020 | $-7.80 | $-7.80 | 0.0% | = MET |
Q4 2019 | Nov 12, 2019 | $-9.80 | $-7.60 | +22.4% | ✓ BEAT |
Q3 2019 | Aug 8, 2019 | $-11.00 | $-11.60 | -5.5% | ✗ MISS |
Q2 2019 | May 9, 2019 | $-8.60 | $-12.20 | -41.9% | ✗ MISS |
Latest News
Frequently Asked Questions about CALA
What is CALA's current stock price?
What is the analyst price target for CALA?
What sector is Calithera Biosciences, Inc. in?
What is CALA's market cap?
Does CALA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CALA for comparison